Delving into the Latest Updates on Hangzhou Ruizhen Pharmaceutical Co., Ltd with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Top II(Topoisomerase II)	1

A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc fusion protein injection) in patients with liver metastases from colorectal cancer.

Start Date27 Apr 2023

Sponsor / Collaborator

Hangzhou Ruizhen Pharmaceutical Co., Ltd

[+1]

CTR20230034

/ RecruitingPhase 2

经肝动脉注射替拉扎明再行肝动脉栓塞（TATE）与KN046联合治疗晚期肝转移性结直肠癌（MSS/ pMMR）的IIA期临床试验

[Translation] A phase IIA clinical trial of transarterial tirapazamine followed by hepatic arterial embolization (TATE) combined with KN046 in the treatment of advanced liver metastatic colorectal cancer (MSS/pMMR)

研究经肝动脉注射替拉扎明再行肝动脉栓塞（TATE）与KN046联合治疗晚期肝转移性结直肠癌MSS/pMMR的有效性和安全性

[Translation]

To investigate the efficacy and safety of transarterial tirapazamine followed by hepatic arterial embolization (TATE) combined with KN046 in the treatment of advanced liver metastatic colorectal cancer MSS/pMMR

Start Date11 Apr 2023

Sponsor / Collaborator

Hangzhou Taibo Pharmaceutical Co., Ltd.

CTR20243479

/ Not yet recruitingPhase 2/3

研究经肝动脉注射替拉扎明后再行肝动脉栓塞（TATE）治疗中期原发性肝细胞癌是否优于传统经肝动脉化疗栓塞（TACE）的多中心、随机、对照、开放的 II/III 期临床试验

[Translation] A multicenter, randomized, controlled, open-label phase II/III clinical trial to investigate whether transarterial embolization (TATE) followed by tirapazamine is superior to conventional transarterial chemoembolization (TACE) in the treatment of intermediate-stage primary hepatocellular carcinoma

评价接受替拉扎明经肝动脉注射后再行肝动脉栓塞术治疗中期原发性肝细胞癌是否优于传统的肝动脉化疗栓塞术，具体评价指标为患者接受 TATE/TACE 治疗后的无进展生存期（PFS）

[Translation]

To evaluate whether transcatheter arterial embolization followed by tirapazamine is superior to conventional transcatheter arterial chemoembolization in the treatment of intermediate-stage primary hepatocellular carcinoma, with the specific evaluation indicator being progression-free survival (PFS) of patients after TATE/TACE treatment

Start Date-

Sponsor / Collaborator

Hangzhou Ruizhen Pharmaceutical Co., Ltd

100 Clinical Results associated with Hangzhou Ruizhen Pharmaceutical Co., Ltd

Login to view more data

0 Patents (Medical) associated with Hangzhou Ruizhen Pharmaceutical Co., Ltd

Login to view more data

100 Deals associated with Hangzhou Ruizhen Pharmaceutical Co., Ltd

Login to view more data

100 Translational Medicine associated with Hangzhou Ruizhen Pharmaceutical Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3

1

Other

Login to view more data